Background Olaparib, a poly(ADPribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to allcomer patients with platinumsensitive, relapsed highgrade serous ovarian cancer We aimed to confirm these findings in patients with a BRCA1 or BRC (BRCA1/2) mutation using a tablet formulation of olaparibEleven (2%) and 3 (<1%) participants in the LA and CAR arms, respectively, met protocoldefined liverrelated stopping criteria Of these, 7 were diagnosed with hepatitis A, 3 with hepatitis B, 2 with hepatitis C, and 1 with hepatitis E;Financial Free College 投資講座3期 has 1 members
ベストコレクション Free 3 期 最高の画像壁紙日本am
Free 3 期